Allergan Announces Completion of Oral Tazarotene Phase Three Studies; Results Now to Be Presented at the Winter AAD

Business Wire, March 5, 2003

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--March 5, 2003

Allergan, Inc. (NYSE:AGN) announced today that it has completed two Phase III trials of an oral formulation of tazarotene investigating its use in the treatment of moderate to severe psoriasis. The trials were multi-center, double-blind, randomized, placebo-controlled, safety and efficacy studies of 12 weeks treatment with oral tazarotene 4.5 mg followed by 12 weeks post treatment follow-up. The data will be presented in the New Therapeutic Options in Psoriasis Therapy portion of the "New & Emerging Therapies" symposium on March 24, 2003 at the American Academy of Dermatology meeting in San Francisco, California.

Tazarotene is a receptor-selective retinoid and is currently marketed in the United States as topical formulations under the tradenames TAZORAC(R) 0.1% and 0.5% and AVAGE(TM) 0.1%

Forward-Looking Statements

Any of the above statements that refer to the Company's estimated or anticipated future results are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses, including the inherent uncertainties associated with the research and development process and the regulatory approval process, technological advances and patents attained by competitors, competitive conditions and changing market conditions, including the performance and acceptance of new products. Accordingly, no assurance can be given that the Company will receive FDA approval to market Oral Tazarotene, or that it will receive approval on an expedited basis, or that, if approved, the Company will be able to successfully launch and market the product. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading " Certain Factors and Trends Affecting Allergan and its Businesses" in Allergan's 2001 Form 10-K and its Form 10-Q for the quarter ended September 27, 2002. Copies of Allergan press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com, or you can contact the Allergan Investor Relations Department by calling 714-246-4636.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.